LUCD (Lucid Diagnostics) Other Current Payables: $0.00 Mil (As of Mar. 2026)


LUCD Lucid Diagnostics Inc LUCD
26 GF Score
Price $1.07
GF Value $0.81
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lucid Diagnostics Other Current Payables?

Lucid Diagnostics LUCD +4.85% 26 Other Current Payables is $0.00 Mil as of Mar. 2026. GuruFocus rates LUCD with a GF Score™ of 26/100 and a GF Value™ of $0.81 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Lucid Diagnostics's Other Current Payables for the quarter that ended in Mar. 2026 was $0.00 Mil.

Lucid Diagnostics's annual Other Current Payables declined from Dec. 2023 ($9.34 Mil) to Dec. 2024 ($0.00 Mil) but then stayed the same from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Lucid Diagnostics Other Current Payables Related Terms

Lucid Diagnostics Other Current Payables Historical Data

* Premium members only.

The historical data trend for Lucid Diagnostics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucid Diagnostics Other Current Payables Chart

Lucid Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial 1.66 4.96 9.34 0.00 0.00

Lucid Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LUCD
26GF Score
Lucid Diagnostics Inc LUCD
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lucid Diagnostics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.00 Mil mean?
Lucid Diagnostics (LUCD) has a Other Current Payables of $0.00 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Lucid Diagnostics and its competitors.
Is Lucid Diagnostics' Other Current Payables too high?
Lucid Diagnostics' current Other Current Payables is $0.00 Mil. Overall, Lucid Diagnostics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Other Current Payables compare to TLSI and INFU?
Lucid Diagnostics' Other Current Payables of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Medical Devices & Instruments company?
A good Other Current Payables depends on the Medical Devices & Instruments industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Lucid Diagnostics and its competitors. Lucid Diagnostics's current Other Current Payables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.81, compared to a current price of $1.07 — trading 31.5% above its estimated fair value. The current Other Current Payables is $0.00 Mil. Lucid Diagnostics' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Other Current Payables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lucid Diagnostics (LUCD) Overvalued in 2026?

Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued. The current stock price of $1.07 is trading 31.5% above its estimated GF Value™ of $0.81. GuruFocus considers Lucid Diagnostics to be Significantly Overvalued.

Key valuation signals for LUCD:

  • Other Current Payables: $0.00 Mil
  • GF Value™: $0.81 vs. price of $1.07 (31.5% above fair value)
  • GF Score™: 26/100 with 5 warning signs

No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lucid Diagnostics Business Description

Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
26GF Score

Get the complete analysis for LUCD

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.07
Price
$0.81
GF Value